RxDoctor Payments Data

Dolores Dominguez Santamaria, MD

Neurology · Pittsburgh, PANPI 1982897864

Payments from drug & device makers

$264,939in general payments, 2019–2025

Across 435 payments — averaging $609.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$69K
  • Amgen$61K
  • Lilly USA, LLC$60K
  • Lundbeck LLC$29K
  • Teva Pharmaceuticals USA, Inc.$26K
  • Biohaven Pharmaceuticals, Inc.$11K
  • plus $10K from 9 others

What the payments were for

  • Consulting fees$23,0809%
  • Speaking & faculty fees$233,24888%
  • Grants$850%
  • Travel & lodging$2,1231%
  • Food & beverage$6,3782%
  • Education$240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$264,939 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$107,620
Medicare patients
207
Services billed
10,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina255$321,762
Emgality PenGalcanezumab-Gnlm217$159,327
UbrelvyUbrogepant114$151,976
Nurtec OdtRimegepant Sulfate124$145,376
QuliptaAtogepant97$105,992
Ajovy AutoinjectorFremanezumab-Vfrm91$84,093
Aimovig AutoinjectorErenumab-Aooe78$72,577
Ajovy SyringeFremanezumab-Vfrm16$11,725
ReyvowLasmiditan Succinate11$7,968
Sumatriptan35$6,947
Zolmitriptan13$6,554
Sumatriptan Succinate216$6,164
Topiramate311$3,064
Carbamazepine ErCarbamazepine23$2,913
Zonisamide72$1,707

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$68,990$579,730466 claims
Lilly USA, LLCReyvow, Olanzapine$59,723$8,04723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →